

Remote monitoring in rheumatoid arthritis

| | | |
|--------------------------|-----------------------------|---------------------------------|
| Submission date | Recruitment status | [X] Prospectively registered |
| 04/05/2022 | No longer recruiting | [X] Protocol |
| Registration date | Overall study status | [] Statistical analysis plan |
| 05/05/2022 | Completed | [X] Results |
| Last Edited | Condition category | [] Individual participant data |
| 27/01/2026 | Musculoskeletal Diseases | |

Plain English summary of protocol

Background and study aims

Rheumatoid arthritis is a common disease affecting 1 in 100 UK adults, causing joint pain, stiffness and fatigue. Patients with rheumatoid arthritis need close monitoring of their arthritis activity to work out the most effective dose of their arthritis drugs. At the moment, this monitoring is done at clinic visits, meaning that patients have to regularly attend hospital. If it were possible for patients to be monitored remotely, this would avoid many trips to hospital and free up clinic appointments for those patients most in need. In this small study, we aim to assess the feasibility of remote monitoring in patients with active rheumatoid arthritis who are starting an arthritis drug.

Who can participate?

Patients with a diagnosis of rheumatoid arthritis, who are starting a new rheumatoid arthritis drug treatment.

What does the study involve?

We will invite 20 patients to take part and will be followed for three months. Patients will complete self-assessments of their arthritis activity using online questionnaires, and their physical activity and heart rate will be measured using small wearable monitors. Patients will also attend for monthly face-to-face visits with a nurse to assess their arthritis activity using standard measurements used in current clinical practice. We will compare remote measurements of arthritis activity with standard face-to-face assessments to assess their accuracy and reliability. Also, information from activity and heart rate monitors will be analysed to look for patterns that may identify when patients have active arthritis. Finally, patients will provide feedback on their experience of remote monitoring, and any aspects for future improvement.

What are the possible benefits and risks of participating?

There will be no direct benefit to participants for participating in this study. They will be making a valuable contribution to our understanding about the feasibility of remote monitoring in rheumatoid arthritis. In the future this may lead to new tools to check people's arthritis between hospital visits, improving the quality and safety of care that we can provide to our patients. There are no obvious disadvantages or risks to taking part in the study. The monitors and smartphone that participants will be required to wear and use are non-invasive and have no associated risks. Sometimes blood tests can cause some minor bruising.

Where is the study run from?

Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

December 2021 to September 2023

Who is funding the study?

The National Institute for Health and Care Research Newcastle Biomedical Research Centre (UK)

Who is the main contact?

Dr Kenneth Baker, kenneth.baker@ncl.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Dr Kenneth Baker

ORCID ID

<https://orcid.org/0000-0002-6735-2911>

Contact details

Translational and Clinical Research Institute,

3rd Floor, William Leech Building,

Medical School, Newcastle University

Newcastle upon Tyne

United Kingdom

NE2 4HH

+44 1912085337

kenneth.baker@ncl.ac.uk

Type(s)

Public

Contact name

Dr Kenneth Baker

Contact details

Translational and Clinical Research Institute,

3rd Floor, William Leech Building,

Medical School, Newcastle University

Newacstle upon Tyne

United Kingdom

NE2 4HH

+44 1912085337

kenneth.baker@ncl.ac.uk

Type(s)

Scientific

Contact name

Dr Kenneth Baker

Contact details

Translational and Clinical Research Institute,
3rd Floor, William Leech Building,
Medical School, Newcastle University
Newcastle upon Tyne
United Kingdom
NE2 4HH
+44 1912085337
kenneth.baker@ncl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

313072

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 313072

Study information

Scientific Title

Remote monitoring of disease and physical activity in rheumatoid arthritis: a pilot study

Study objectives

To demonstrate the feasibility of remote disease activity monitoring in participants with rheumatoid arthritis, to support a future clinical efficacy trial.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/05/2022, North of Scotland Research Ethics Committee (Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE, UK; +44 (0)1224558458; gram.nosres@nhs.scot), ref: 22/NS/0072

Study design

Single centre observational longitudinal cohort study

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

In this pilot study, we propose to recruit 20 participants with rheumatoid arthritis (RA) with active disease who are newly starting a disease modifying antirheumatic drug (DMARD). Participants will be followed for 3 months, with monthly face-to-face visits to measure the disease activity in 28 joints (DAS28) score. Throughout the study, participants will complete weekly patient-reported outcome measures (PROMs) in the form of the simple 5-question RA Disease Activity Index 5 (RADAI-5), captured electronically using the British Society for Rheumatology ePROMs online portal, with weekly email reminders to support participant uptake. In addition, at each monthly visit participants will be provided with activity trackers (lower back and wrist – Axivity AX6) and a combined activity and cardiorespiratory monitor (VitalPatch) to be worn for 7 days. Additional PROMs including FACIT-F and MFS (fatigue), HAQ-DI (physical function), PHQ-2 (anxiety/depression) and EQ-5D-5L (general health) will be captured at the monthly visits, in order to collect information necessary for interpretation of the activity monitor data.

Intervention Type

Not Specified

Primary outcome(s)

1. Arthritis activity measured using the disease activity score in 28 joints (DAS28) score at baseline, week 4, week 8 and week 12.
2. Arthritis activity measured using the rheumatoid arthritis disease activity index 5 (RADAI-5) at baseline, week 4, week 8 and week 12

Key secondary outcome(s)

1. Physical activity measured by Axivity AX6 devices at baseline, week 4, week 8 and week 12
2. Cardiorespiratory activity measured by VitalPatch devices at baseline, week 4, week 8 and week 12
3. Fatigue measured by the FACIT-F questionnaire at baseline, week 4, week 8 and week 12
4. Fatigue measured by the MFS questionnaire at baseline, week 4, week 8 and week 12
5. Physical function measured by the HAQ-DI questionnaire at baseline, week 4, week 8 and week 12
6. Anxiety and depression measured by the PHQ-2 questionnaire at baseline, week 4, week 8 and week 12
7. General health measured by the EQ-5D-5L questionnaire at baseline, week 4, week 8 and week 12

Completion date

30/09/2023

Eligibility

Key inclusion criteria

1. Diagnosis of rheumatoid arthritis according to the 1987 American College of Rheumatology (ACR) or 2010 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria applied at any time since diagnosis.
2. Participant about to commence (i.e. planned within next 4 weeks), or recently commenced (i.e. within past 8 weeks), a new disease-modifying anti-rheumatic drug (i.e. conventional synthetic DMARD, Janus-kinase inhibitor or biologic therapy)
3. Able to walk at least four metres independently without walking aids
4. Participant willing to commit to complete remote monitoring measurements and wear monitoring devices

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

99 years

Sex

All

Total final enrolment

13

Key exclusion criteria

1. Unable to read or communicate in English
2. Current participation within an interventional clinical trial (participation in another observational trial is permitted)
3. Inability to provide informed consent
4. Age less than 18 years
5. Current diagnosis of a movement disorder
6. Current pregnancy

Date of first enrolment

01/06/2022

Date of final enrolment

30/06/2023

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Freeman Hospital

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Road
High Heaton
Newcastle upon Tyne
England
NE7 7DN

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust

ROR

<https://ror.org/05p40t847>

Funder(s)

Funder type

Government

Funder Name

NIHR Newcastle Biomedical Research Centre

Alternative Name(s)

Newcastle Biomedical Research Centre, Newcastle NIHR Biomedical Research Centre

Funding Body Type

Private sector organisation

Funding Body Subtype

Research institutes and centers

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|--------------------------------------|-----------|--------------|------------|----------------|-----------------|
| Basic results | | | 27/01/2026 | No | No |
| HRA research summary | | | 28/06/2023 | No | No |
| Protocol file | version 6 | 11/01/2023 | 27/01/2026 | No | No |